卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究

doi:10.6040/j.issn.1673-3770.0.2021.263

摘要/Abstract

摘要： 目的探究卵磷脂络合碘胶囊联合雷珠单抗对视网膜静脉阻塞继发黄斑水肿(RVO-ME)的临床疗效。方法选取2020年1月至2021年2月就诊的40例40眼RVO-ME患者为研究对象,随机分为两组,雷珠单抗组和卵磷脂联合组,雷珠单抗组19例,卵磷脂联合组 21例,雷珠单抗组每4周给予玻璃体腔内注射雷珠单抗治疗,卵磷脂联合组是在雷珠单抗组治疗的基础上加用卵磷脂络合碘胶囊治疗,治疗 12 周,治疗期间每4周随访一次,观察治疗前后眼压、最佳矫正视力(BCVA)、眼底出血面积、黄斑中心区厚度(CMT)、中心凹无血管区(FAZ)、脉络膜血流面积(CFA)、浅层视网膜毛细血管层(SCP)和深层视网膜毛细血管层(DCP)的血管密度变化,并观察有无不良事件和不良反应的发生。结果两组患者各治疗时间点BCVA(LogMAR)、CMT均较治疗前改善,组间比较均无统计学差异。FAZ、SCP两组患者治疗前后无统计学差异,且组间比较无统计学差异。两组患者各治疗时间点眼底出血面积均较治疗前减少,卵磷脂联合组各治疗时间点的眼底出血吸收情况均优于雷珠单抗组,差异具有统计学意义。两组患者治疗前后CFA有增加趋势,差异具有统计学意义,组间比较无统计学差异。随访12周,两组患眼DCP呈明显增加趋势,差异具有统计学意义,且卵磷脂联合组DCP改善情况优于雷珠单抗组,差异具有统计学意义。结论卵磷脂络合碘胶囊辅助治疗视网膜静脉阻塞能更好地促进眼底出血的吸收、增加深层视网膜毛细血管密度,无明显不良反应。

关键词: 视网膜静脉阻塞, 雷珠单抗, 卵磷脂络和碘, 黄斑水肿

Abstract: Objective To explore the clinical efficacy of lecithin complex iodine capsule combined with ranibizumab in the treatment of macular edema secondary to retinal vein occlusion(RVO-ME). Methods 40 patients(40 eyes)with RVO-ME who were admitted to our hospital from January 2020 to February 2021 were randomly divided into two groups: ranibizumab group and lecithin combination group, 19 cases(19 eyes)in ranibizumab group and 21 cases(21 eyes)in lecithin combination group. The patients in ranibizumab group were treated with intravitreal injection of ranibizumab every 4 weeks, and the patients in lecithin combined group were treated with lecithin complex iodine capsule combined with ranibizumab every 4 weeks, follow-up every 4 weeks during the 12 weeks observation period, The changes of intraocular pressure(IOP), best-corrected visual acuity(BCVA), fundus bleeding area, central macular thickness(CMT), fovea avascular zone(FAZ), choriocaphillaris flow area(CFA), superficial capillary plexus(SCP)and deep capillary plexus(DCP)were observed before and after treatment. Results BCVA(LogMAR)and CMT of the two groups at each treatment time point were significantly improved compared with those before treatment, and there was no significant difference between the two groups. FAZ and SCP: there was no significant difference between the two groups before and after treatment, and there was no significant difference between the two groups. Fundus hemorrhage area: the fundus hemorrhage area of the two groups at each treatment time point was significantly lower than that before treatment. The fundus hemorrhage absorption of the lecithin combined group at each treatment time point was better than that of the ranibizumab group, and the difference was statistically significant. CFA in the eyes of the two groups increased before and after teatment, the difference was statistically significant, and there was no significant difference between the two groups. After 12 weeks of follow-up, DCP in the eyes of the two groups showed a significant increase trend, the difference was statistically significant, and the improvement of DCP in lecithin combined group was better than that in leizumab group, the difference was statistically significant. Conclusions Lecithin complex iodine capsule in the adjuvant treatment of retinal vein occlusion can achieve a better result in promoting the absorption of fundus hemorrhage and increase the density of deep retinal capillaries.

Key words: Retinal Vein Occlusion, Ranibizumab, Lecithin Complex Iodine, Macular Edema

中图分类号:

R774.1

顾冉冉,李凤娇,焦万珍,崔艳艳,赵博军. 卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 46-50.

GU Ranran, LI Fengjiao, JIAO Wanzhen, CUI Yanyan, ZHAO Bojun. Clinical efficacy of lecithin complex iodine capsule in the adjuvant treatment of retinal vein occlusion[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 46-50.

参考文献

[1] Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: Beyond the surface[J]. Prog Retin Eye Res, 2018, 63: 20-68. doi:10.1016/j.preteyeres.2017.10.006.
[2] Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010,117(2): 313-319.e1. doi:10.1016/j.ophtha.2009.07.017.
[3] Ng DSC, Fung NSK, Yip FLT, et al. Ranibizumab for myopic choroidal neovascularization[J]. Expert Opin Biol Ther, 2020, 20(12): 1385-1393. doi:10.1080/14712598.2021.1830969.
[4] Campa C, Alivernini G, Bolletta E, et al. Anti-VEGF therapy for retinal vein occlusions[J]. Curr Drug Targets, 2016, 17(3): 328-336. doi:10.2174/1573399811666150615151324.
[5] 詹凌. 观察卵磷脂络合碘片(沃丽汀)治疗黄斑水肿的临床疗效[J]. 2016, 32(6): 887-889, 891. doi:10.3969/j.issn.1000-484X.2016.06.026. ZHAN Ling. Study on efficacy of iodized lecithin tablets in treatment of macular edema[J]. Chinese Journal of Immunology, 2016, 32(6): 887-889, 891. doi:10.3969/j.issn.1000-484X.2016.06.026.
[6] 栗洵, 陈琳琳. 激光光凝眼底联合卵磷脂络合碘片治疗中心性浆液性脉络膜视网膜病变的效果[J]. 中国医药导报, 2015, 12(36): 101-104. LI Xun, CHEN Linlin. Effect of laser photocoagulation fundus combined with Iodized Lecithin Tablets in the treatment of central serous chorioretinopathy[J]. China Medical Herald, 2015, 12(36): 101-104.
[7] Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European society of Retina specialists(EURETINA)[J]. Ophthalmol J Intd' Ophtalmologie Int J Ophthalmol Zeitschrift Fur Augenheilkunde, 2019, 242(3): 123-162. doi:10.1159/000502041.
[8] 韩克阳, 于贝贝, 赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131. doi:10.1159/000455809.0.2017.515. HAN Keyang, YU Beibei, ZHAO Bojun. Morphological structure analysis of the macular area after anti-VEGF treatment for short-term retinal vein occlusion[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 129-131.doi:10.1159/000455809.0.2017.515.
[9] Cunha-Vaz J. The blood-retinal barrier in the management of retinal disease: EURETINA award lecture[J]. Ophthalmologica, 2017, 237(1): 1-10. doi:10.1159/000455809.
[10] Cachafeiro M, Bemelmans AP, Samardzija M, et al. Hyperactivation of Retina by light in mice leads to photoreceptor cell death mediated by VEGF and retinal pigment epithelium permeability[J]. Cell Death Dis, 2013, 4: e781. doi:10.1038/cddis.2013.303.
[11] Xia JP, Wang S, Zhang JS. The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion[J]. Biochem Biophys Res Commun, 2019,508(4): 1264-1270. doi:10.1016/j.bbrc.2018.12.049.
[12] Sugimoto M, Kondo M. Lecithin-bound iodine prevents disruption of tight junctions of retinal pigment epithelial cells under hypoxic stress[J]. J Ophthalmol, 2016, 2016: 9292346. doi:10.1155/2016/9292346.
[13] Lee A, Taylor P, Kalpathy-Cramer J, et al. Machine learning has arrived![J]. Ophthalmology, 2017, 124(12): 1726-1728. doi:10.1016/j.ophtha.2017.08.046.
[14] Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future[J]. Stroke Vasc Neurol, 2017, 2(4): 230-243. doi:10.1136/svn-2017-000101.
[15] 王丽雯, 崔林, 邹吉新, 等. OCTA在视网膜静脉阻塞诊疗中的应用价值[J]. 国际眼科杂志, 2019, 19(8): 1361-1364. doi:10.3980/j.issn.1672-5123.2019.8.22. WANG Liwen, CUI Lin, ZOU Jixin, et al. Application value of OCTA examination in diagnosis and treatment of retinal vein occlusion[J]. International Eye Science, 2019, 19(8): 1361-1364. doi:10.3980/j.issn.1672-5123.2019.8.22.
[16] Okamoto M, Yamashita M, Sakamoto T, et al. Choroidal blood flow and thickness as predictors for response to anti-vascular endothelial growth factor therapy in macular edema secondary to branch retinal vein occlusion[J]. Retina, 2018, 38(3): 550-558. doi:10.1097/IAE.0000000000001566.
[17] Lee H, Kim MA, Kim HC, et al. Characterization of microvascular tortuosity in retinal vein occlusion utilizing optical coherence tomography angiography[J]. Sci Rep, 2020, 10(1): 17788. doi:10.1038/s41598-020-74871-7.
[18] 金昕, 谭薇, 李燕. 量化OCTA在视网膜静脉阻塞中的应用[J]. 国际眼科杂志, 2021, 21(4): 711-714. doi:10.3980/j.issn.1672-5123.2021.4.30. JIN Xin, TAN Wei, LI Yan. Application of quantitative OCTA in retinal vein occlusion[J]. International Eye Science, 2021, 21(4): 711-714.doi:10.3980/j.issn.1672-5123.2021.4.30.

相关文章 15

[1]	张陶然,王薇,李明铭,黄映湘. IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 68-71.
[2]	韩克阳,于贝贝,赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131.
[3]	刘建波,张环. 超声乳化联合玻璃体腔药物注射治疗白内障合并糖尿病性黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 99-104.
[4]	梁倩倩,杨庭骅,赵博军. 光学相干层析血管扫描在视网膜静脉阻塞中的应用[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 139-142.
[5]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[6]	靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
[7]	严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[8]	韩克阳,王淑雅,焦芮,于贝贝综述, 赵博军审校. 视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 123-126.
[9]	赵露,谢国丽,王艳玲. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者眼血流动力学的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 101-104.
[10]	严晓腾,冯军,康欣乐. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 105-108.
[11]	邢凯,亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 80-82.
[12]	柴雪荣, 张士玺, 陶钰, 申家泉. 玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的效果评价[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 72-75.
[13]	严晓腾, 冯军, 康欣乐. 曲安奈德玻璃体腔注射联合格栅样光凝治疗囊样黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 60-63.
[14]	孙洪义, 张晗. 2型糖尿病患者超声乳化白内障摘除并人工晶体植入手术后黄斑区光学相干断层扫描改变[J]. 山东大学耳鼻喉眼学报, 2014, 28(6): 72-76.
[15]	龚斌, 范传峰, 王玉. 抗VEGF药物(雷珠单抗)治疗不同病程湿性年龄相关性黄斑变性62例[J]. 山东大学耳鼻喉眼学报, 2014, 28(5): 58-61.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed